Browsing by Autor "Gerardo Quintana"

Now showing 1 - 2 of 2

Economic Evaluations in Systemic Lupus Erythematosus
(2011) Gerardo Quintana; Helena Avella; Paola Coral-Alvarado
This chapter shows a historical description of approaches to economic evaluation in SLE, both at national and international framework and highlighting the main elements that must be considered in clinical practice and decisions to avoid increasing the economic burden of health care. A non-systematic review of all published literature in English, French and Spanish from 1990 to April 2011 was performed using Medline, Pubmed, Cochrane, Lilacs and Scielo in peer-reviewed articles, including the Mesh-terms of systemic lupus erythematosus, direct costs, indirect and intangible cost, economic impact, disease burden, Cost-of-illness (COI) studies, pharmacoeconomics analysis, cost-effectiveness and costutility. It will have three types of approaches: the economic impact of the disease, COI studies and finally, a complete pharmacoeconomic assessment.
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis <scp>SOLAPSO</scp> – Sociedad Latinoamericana de Psoriasis <i>(Latin American Psoriasis Society)</i>
(Wiley, 2019) Nora Kogan; Nélida Raimondo; Simón Gusis; Ariel Izcovich; Jorge A. Abarca Duran; Lilia Barahona‐Torres; Orestes Blanco; Gerardo Quintana; María Cecilia Briones; Carla Castro
This Clinical Practice Guideline on the systemic treatment of Psoriasis includes the recommendations elaborated by a panel of experts from the Latin American Psoriasis Society SOLAPSO, who assessed the quality of the available evidence using the GRADE system and the PICO process to guide the literature search. To answer each question, the experts discussed the results of randomized controlled trials, observational studies and metanalysis evaluating the interventions identified (non-biologics, biologics and phototherapy) in different populations of patients with moderate to severe plaque-psoriasis, which was summarized in Tables ad-hoc. The main end-points considered to assess efficacy were PASI 50, 75, 90 and 100, PGA 0-1 and significant improvement of health-related quality of life. Specific adverse events, either severe or leading to treatment interruption, were also evaluated. The 31 recommendations included in this CPG follow the structure proposed by GRADE: direction (for or against) and strength (strong or weak). The goal of this CPG is to improve the management of patients with psoriasis by recommending interventions of proved benefit and providing a reference standard for the treating physician. Adhering to the contents of this CPG does not guarantee therapeutic success. The final decision on the specific treatment is the responsibility of the physician based on the individual circumstances and considering the values, the preferences and the opinions of the patient or caregivers.